Print Page Print Page
E-mail Page E-mail Page
RSS Feeds RSS Feeds
X
Share Page Share Page
E-mail Alerts E-mail Alerts
Financial Tear Sheet Financial Tear Sheet

Investor Relations

Overview
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEX™ is a steroid in development for the treatment of Ménière's disease and other balance and hearing disorders. Two Phase 3 trials in Ménière's disease patients are ongoing, AVERTS-1 in the United States and AVERTS-2 in Europe, with AVERTS-1 results expected in September 2017 and AVERTS-2 results expected by the end of 2017. In addition, a Phase 2 trial of OTIVIDEX is ongoing in patients at risk for cisplatin-induced hearing loss. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expected to be initiated by the end of 2017. A fourth program targeting sensorineural hearing loss including age-related hearing loss is in preclinical development. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.
Stock Quote
OTIC (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$18.75
Change (%) Stock is Down 0.1 (0.53%)
Volume79,570
Data as of 08/18/17 1:48 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: OTIC.OQ.  Currently trading at $18.75 with a 52 week high of $20.15 and a 52 week low of $11.30.
Recent NewsMore >>
DateTitle 
08/03/17Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
07/27/17Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate UpdatePrinter Friendly Version
Investor Presentations
Download Documentation Corporate Presentation – August 3, 2017
Download Documentation 2017 KOL Breakfast Event – June 27, 2017
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Otonomy Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources